Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver diseases and can progress to advanced fibrosis and end-stage liver disease. Thus, intensive research has been performed to develop noninvasive methods for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Currently...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Endocrine Society
2020-06-01
|
| Series: | Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.e-enm.org/upload/pdf/EnM-2020-35-2-243.pdf |
| _version_ | 1811273284128342016 |
|---|---|
| author | Dae Ho Lee |
| author_facet | Dae Ho Lee |
| author_sort | Dae Ho Lee |
| collection | DOAJ |
| description | Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver diseases and can progress to advanced fibrosis and end-stage liver disease. Thus, intensive research has been performed to develop noninvasive methods for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Currently, no single noninvasive tool covers all of the stages of pathologies and conditions of NAFLD, and the cost and feasibility of known techniques are also important issues. Blood biomarkers for NAFLD may be useful to select subjects who need ultrasonography (US) screening for NAFLD, and noninvasive tools for assessing fibrosis may be helpful to exclude the probability of significant fibrosis and to predict advanced fibrosis, thus guiding the decision of whether to perform liver biopsy in patients with NAFLD. Among various methods, magnetic resonance-based methods have been shown to perform better than other methods in assessing steatosis as well as in detecting hepatic fibrosis. Many genetic markers are associated with the development and progression of NAFLD. Further well-designed studies are needed to determine which biomarker panels, imaging studies, genetic marker panels, or combinations thereof perform well for diagnosing NAFLD, differentiating NASH and fibrosis, and following-up NAFLD, respectively. |
| first_indexed | 2024-04-12T22:56:21Z |
| format | Article |
| id | doaj.art-f7e7aacdc4c141fb8985cd484e188430 |
| institution | Directory Open Access Journal |
| issn | 2093-596X 2093-5978 |
| language | English |
| last_indexed | 2024-04-12T22:56:21Z |
| publishDate | 2020-06-01 |
| publisher | Korean Endocrine Society |
| record_format | Article |
| series | Endocrinology and Metabolism |
| spelling | doaj.art-f7e7aacdc4c141fb8985cd484e1884302022-12-22T03:13:11ZengKorean Endocrine SocietyEndocrinology and Metabolism2093-596X2093-59782020-06-0135224325910.3803/EnM.2020.35.2.2432035Noninvasive Evaluation of Nonalcoholic Fatty Liver DiseaseDae Ho LeeNonalcoholic fatty liver disease (NAFLD) is the most prevalent liver diseases and can progress to advanced fibrosis and end-stage liver disease. Thus, intensive research has been performed to develop noninvasive methods for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Currently, no single noninvasive tool covers all of the stages of pathologies and conditions of NAFLD, and the cost and feasibility of known techniques are also important issues. Blood biomarkers for NAFLD may be useful to select subjects who need ultrasonography (US) screening for NAFLD, and noninvasive tools for assessing fibrosis may be helpful to exclude the probability of significant fibrosis and to predict advanced fibrosis, thus guiding the decision of whether to perform liver biopsy in patients with NAFLD. Among various methods, magnetic resonance-based methods have been shown to perform better than other methods in assessing steatosis as well as in detecting hepatic fibrosis. Many genetic markers are associated with the development and progression of NAFLD. Further well-designed studies are needed to determine which biomarker panels, imaging studies, genetic marker panels, or combinations thereof perform well for diagnosing NAFLD, differentiating NASH and fibrosis, and following-up NAFLD, respectively.http://www.e-enm.org/upload/pdf/EnM-2020-35-2-243.pdfevaluationnon-alcoholic fatty liver diseaseliver steatosisfibrosisbiomarkers |
| spellingShingle | Dae Ho Lee Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease Endocrinology and Metabolism evaluation non-alcoholic fatty liver disease liver steatosis fibrosis biomarkers |
| title | Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease |
| title_full | Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease |
| title_fullStr | Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease |
| title_full_unstemmed | Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease |
| title_short | Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease |
| title_sort | noninvasive evaluation of nonalcoholic fatty liver disease |
| topic | evaluation non-alcoholic fatty liver disease liver steatosis fibrosis biomarkers |
| url | http://www.e-enm.org/upload/pdf/EnM-2020-35-2-243.pdf |
| work_keys_str_mv | AT daeholee noninvasiveevaluationofnonalcoholicfattyliverdisease |